ArticleOncogene2022
TP53, CDKN2A/P16, and NFE2L2/NRF2 regulate the incidence of pure- and combined-small cell lung cancer in mice.
Erratum issuedAbstract read
In one paragraph
Article in Oncogene, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 15 papers.
0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Immunological and prognostic impact of NRF2 in high grade serous ovarian cancer.Genes and immunity · 2026Article
- Differential roles of Rad18 in repressing carcinogen- and oncogene-driven mutagenesisNAR cancer · 2026Article
- Differential roles of Rad18 in repressing carcinogen- and oncogene-driven mutagenesisbioRxiv : the preprint server for biology · 2025Article
- Activating NRF2Cancer gene therapy · 2025Article
- [A Case of Combined Small Cell Lung Cancer and Literature Review].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2025Review
- Epigenetic modifications in early stage lung cancer: pathogenesis, biomarkers, and early diagnosis.MedComm · 2025Review
- The Impact of Genetic Mutations on the Efficacy of Immunotherapies in Lung Cancer.International journal of molecular sciences · 2024Review
- YAP1 Status Defines Two Intrinsic Subtypes of LCNEC with Distinct Molecular Features and Therapeutic Vulnerabilities.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Article
- Review
- Prognosis of immunotherapy for non-small cell lung cancer withJournal of thoracic disease · 2024Article
- Carcinogenic effect of human tumor-derived cell-free filtrates in nude mice.Frontiers in molecular biosciences · 2024Article
- The Crosstalk between Autophagy and Nrf2 Signaling in Cancer: from Biology to Clinical Applications.International journal of biological sciences · 2024Review
- Distinct Nrf2 Signaling Thresholds Mediate Lung Tumor Initiation and Progression.Cancer research · 2023Article
- The Multi-Faceted Consequences of NRF2 Activation throughout Carcinogenesis.Molecules and cells · 2023Review
- Combined small cell lung cancer: current progress and unmet needs.American journal of cancer research · 2023Review
Corrections and comments
- Erratum issued
Authors and funding
15 authors.
Samera H HamadLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA.
Stephanie A MontgomeryLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA.
Jeremy M SimonLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA.
Brittany M BowmanLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA.
Kyle B SpainhowerDepartment of Oncological Sciences, School of Medicine, University of Utah, Salt Lake City, UT, USA.
Ryan M MurphyDepartment of Pharmacology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA.
Erik S KnudsenRoswell Park Comprehensive Cancer Center, Buffalo, NY, USA.ORCID http://orcid.org/0000-0002-5130-5969
Suzanne E FentonDivision of National Toxicology Program, NIEHS/NIH, Research Triangle Park, NC, USA.
Scott H RandellMarsico Lung Institute, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA.
Jeremiah R HoltUniversity of Tennessee Health Science Center for Cancer Research, Department of Medicine, Division of Hematology and Oncology, University of Tennessee, Memphis, TN, USA.ORCID http://orcid.org/0000-0002-5201-5015
D Neil HayesUniversity of Tennessee Health Science Center for Cancer Research, Department of Medicine, Division of Hematology and Oncology, University of Tennessee, Memphis, TN, USA.
Agnieszka K WitkiewiczRoswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Trudy G OliverDepartment of Oncological Sciences, School of Medicine, University of Utah, Salt Lake City, UT, USA.ORCID http://orcid.org/0000-0003-2082-2397
M Ben MajorLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA. bmajor@wustl.edu.
Bernard E WeissmanLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA. weissman@med.unc.edu.ORCID http://orcid.org/0000-0002-1827-2309
Funding
TOXICOLOGYT32ES007126 · NIEHS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ILONA JASPERS, Bernard E. Weissman · 1985 to 2026
$13.0MCoordinating center for the NCI small cell lung cancer research consortiumU24CA213274 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Lauren Averett Byers, JOHN D. MINNA · 2017 to 2026
$12.9MGenomic and Functional Identification of Chemotherapy Resistance Mechanisms in Small Cell Lung CancerU01CA231844 · NCI · WASHINGTON UNIVERSITY · PI GOVINDAN, RAMASWAMY, GRIFFITH, OBI L. · 2018 to 2022
$3.1MThe Role of Protein Kinases in NRF2-driven Lung Squamous Cell CarcinomaR01CA216051 · NCI · WASHINGTON UNIVERSITY · PI MAJOR, MICHAEL BENJAMIN, WEISSMAN, BERNARD E. · 2018 to 2022
$2.5MPro-tumor functions of neutrophils in squamous cell lung cancerR01CA244841 · NCI · UNIVERSITY OF UTAH · PI OLIVER, TRUDY GALE · 2020 to 2024
$2.0MNCI NIH HHS R01 CA216051NCI NIH HHS R01 CA244841NCI NIH HHS U01 CA231844NCI NIH HHS U24 CA213274NIEHS NIH HHS T32 ES007126
Abstract
Studies have shown that Nrf2
Indexed as
Carcinoma, NeuroendocrineLung NeoplasmsSmall Cell Lung CarcinomaAnimalsCyclin-Dependent Kinase Inhibitor p16Homeodomain ProteinsHumansIncidenceMiceNF-E2-Related Factor 2Nuclear ProteinsTranscription FactorsTumor Suppressor Protein p53CDKN2A protein, humanCdkn2a protein, mouseCyclin-Dependent Kinase Inhibitor p16Homeodomain ProteinsNFE2L2 protein, humanNfe2l2 protein, mouseNF-E2-Related Factor 2Nkx1-2 protein, mouseNuclear ProteinsTP53 protein, humanTranscription FactorsTumor Suppressor Protein p53
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.